Collaborative Projects Support
Alnylam Pharmaceuticals’ Collaborative Projects Support grant funds joint research and educational projects focused on advancing science in ATTR amyloidosis, AHP, and PH1.
Browse similar grants
Funder: Alnylam Pharmaceuticals
Due Dates: Rolling (submit at least 45 days before project start)
Funding Amounts: No set minimum or maximum; funding and in-kind support determined case-by-case per collaboration.
Summary: Supports joint projects with external organizations to advance science, healthcare, or education, focusing on Alnylam’s key disease areas.
Description
Alnylam Pharmaceuticals provides support for collaborative projects with external organizations—such as academic institutions, healthcare organizations, nonprofits, and professional associations—to jointly advance scientific research, healthcare delivery, or educational initiatives. These collaborations emphasize shared planning and execution, leveraging the expertise and resources of both Alnylam and partners to achieve clearly defined goals, especially in Alnylam’s therapeutic focus areas: transthyretin-mediated amyloidosis (ATTR amyloidosis), acute hepatic porphyria (AHP), and primary hyperoxaluria type 1 (PH1). Projects may include research, educational programs, or quality improvement initiatives that improve patient care or health system performance.
